Meridian Bioscience Receives Health Canada Approval for Alethia® CMV Assay, Expanding Molecular Diagnostics Portfolio
Meridian Bioscience, Inc., a global provider of diagnostic testing solutions and life science raw materials, has announced that Health Canada has granted a medical device license for the Alethia® Cytomegalovirus (CMV) Assay, expanding the company’s molecular diagnostics portfolio in the Canadian market. The newly approved assay strengthens Meridian’s Alethia testing menu by adding a rapid molecular diagnostic solution for congenital cytomegalovirus (CMV), one of the most common congenital infections affecting newborns worldwide.
The approval marks another milestone in Meridian’s strategy to broaden access to fast, accurate molecular diagnostics that support timely clinical decision-making. With the addition of the CMV assay, healthcare providers and laboratories in Canada will have access to a rapid test designed to detect congenital CMV using saliva samples, helping clinicians identify infected newborns early and initiate appropriate follow-up care when necessary.
The newly licensed assay joins Meridian’s existing Alethia molecular testing portfolio, which already includes assays for Clostridioides difficile (C. difficile), Group A Streptococcus, Group B Streptococcus, malaria, Mycoplasma, and pertussis, providing laboratories with a broader range of diagnostic solutions on a single testing platform.
Expanding Meridian’s Molecular Testing Portfolio
The Health Canada authorization represents an important expansion of Meridian Bioscience’s molecular diagnostics offerings in Canada, reflecting growing demand for rapid infectious disease testing that can be performed with streamlined laboratory workflows.
Healthcare systems increasingly rely on molecular diagnostic technologies because they offer higher sensitivity and specificity than many conventional testing methods while producing results much faster. Early and accurate diagnosis enables physicians to make informed treatment decisions, reduce unnecessary interventions, and improve patient outcomes.
By incorporating the Alethia CMV assay into its existing portfolio, Meridian provides laboratories with another diagnostic option capable of supporting newborn screening and congenital infection assessment.
The company continues to expand its menu of molecular assays to address a wide range of infectious diseases affecting patients across different healthcare settings.
Alethia Platform Designed for Rapid Molecular Testing
The Alethia molecular diagnostics platform has been developed to deliver reliable molecular test results in less than one hour, allowing clinicians to obtain actionable diagnostic information within a clinically meaningful timeframe.
Unlike many traditional molecular testing systems that require complex laboratory infrastructure, the Alethia platform features a compact design and simplified workflow intended to improve laboratory efficiency while reducing operational complexity.
Its relatively small footprint makes the system suitable for laboratories with limited space, while the straightforward testing process enables personnel to perform molecular diagnostics with minimal workflow disruption.
Rapid turnaround times are particularly valuable in infectious disease diagnosis, where early detection can influence treatment decisions, patient management, infection control measures, and follow-up planning.
The platform has been designed to support evidence-based clinical care by providing accurate molecular results quickly enough to assist healthcare professionals during critical decision-making.
LAMP Technology Provides Efficient Molecular Detection
A distinguishing feature of the Alethia platform is its use of loop-mediated isothermal amplification (LAMP) technology.
Unlike conventional polymerase chain reaction (PCR) testing, which requires repeated heating and cooling cycles to amplify genetic material, LAMP technology performs DNA amplification at a constant temperature.
This simplified amplification process reduces equipment complexity while maintaining high analytical sensitivity.
The technology offers several practical advantages, including:
- Rapid amplification of target genetic material
- Simplified laboratory workflow
- Reduced instrumentation requirements
- Cost-effective molecular testing
- Reliable detection of infectious pathogens
These characteristics have contributed to increasing adoption of LAMP-based diagnostics across healthcare settings where rapid, accurate molecular testing is essential.
By utilizing LAMP technology, Meridian aims to provide laboratories with an efficient molecular testing solution that balances diagnostic performance with operational simplicity.
Addressing the Challenge of Congenital CMV
The newly approved Alethia CMV assay addresses an important area of neonatal healthcare.
Cytomegalovirus (CMV) is one of the most common viral infections worldwide. While CMV infection often causes few or no symptoms in healthy adults, infection during pregnancy can result in congenital CMV, in which the virus is transmitted from mother to fetus before birth.
Congenital CMV is recognized as the most common congenital infection affecting newborns.
According to epidemiological data, nearly one in four women carry CMV infection, making maternal exposure relatively common.
Each year, approximately one in every 200 infants is born with congenital CMV infection.
Despite its prevalence, awareness of congenital CMV remains limited. Studies indicate that the majority of pregnant women have little or no knowledge of the virus or its potential impact on fetal development.
This lack of awareness can contribute to delayed diagnosis, as many infected newborns appear healthy immediately after birth despite being at risk for future complications.
Importance of Early Detection
Early identification of congenital CMV plays a critical role in neonatal care.
Although some infected infants display symptoms shortly after birth, many newborns with congenital CMV initially appear clinically normal.
However, untreated congenital CMV may later contribute to complications including:
- Hearing loss
- Vision impairment
- Developmental delays
- Neurological disorders
- Learning disabilities
- Motor impairment
Because many of these complications develop gradually over time, identifying infection during the newborn period allows healthcare providers to initiate appropriate monitoring and evaluate whether additional medical interventions are warranted.
Early diagnosis also enables physicians to educate families regarding potential long-term health considerations and schedule ongoing developmental assessments when appropriate.
The Alethia CMV assay has been developed to support this early diagnostic process by enabling rapid molecular detection shortly after birth.
Saliva-Based Testing Simplifies Sample Collection
One of the key advantages of the Alethia CMV assay is its use of saliva as the specimen type.
Collecting saliva samples from newborns is generally simple, non-invasive, and well tolerated.
Compared with more invasive sampling procedures, saliva collection can often be completed quickly with minimal discomfort for infants while simplifying specimen collection for healthcare providers.
The ease of sample collection may facilitate broader implementation of congenital CMV testing in hospitals and maternity care settings.
Once collected, the saliva sample can be analyzed using the Alethia platform, providing highly sensitive molecular detection with a rapid turnaround time.
Fast diagnostic results can assist clinicians before newborns are discharged from the hospital, allowing additional evaluation or follow-up planning when necessary.
Supporting Physicians and Families
Early diagnosis of congenital CMV provides benefits for both healthcare professionals and families.
For physicians, molecular confirmation of CMV infection supports evidence-based clinical decision-making by identifying newborns who may require further evaluation, specialist referral, or ongoing developmental monitoring.
For parents, early testing provides valuable information about their child’s health before leaving the hospital.
Understanding whether a newborn has congenital CMV enables families to work closely with healthcare providers to establish appropriate follow-up care and monitor for potential complications that may emerge during infancy or early childhood.
Earlier diagnosis also reduces uncertainty and allows medical teams to implement individualized care plans based on each infant’s clinical needs.
Company Perspective
Michelle Bosch, Vice President of Global Marketing at Meridian Bioscience, highlighted the importance of expanding the Alethia testing menu with the newly licensed CMV assay.
She noted that the approval allows Meridian to offer an important molecular diagnostic solution for healthcare providers throughout Canada while strengthening the company’s presence in the country’s diagnostic testing market.
Bosch also emphasized the advantages of saliva-based testing, explaining that the assay offers an easy-to-collect specimen option for congenital CMV diagnosis.
According to Bosch, the Alethia CMV assay provides clinicians with a valuable molecular tool to support accurate diagnosis and informed clinical management of newborns with suspected congenital CMV infection.
Strengthening Access to Molecular Diagnostics
The Health Canada approval of the Alethia CMV assay represents another step in Meridian Bioscience’s efforts to expand access to rapid molecular diagnostic testing for infectious diseases. By adding congenital CMV detection to its existing Alethia menu, the company enhances the platform’s clinical utility while providing Canadian laboratories with another efficient diagnostic option.
As awareness of congenital CMV continues to grow, early molecular testing is expected to play an increasingly important role in neonatal healthcare. Rapid diagnosis, combined with simple saliva-based specimen collection and efficient laboratory workflows, can help support timely clinical decision-making and improve opportunities for early intervention when appropriate. Through continued expansion of its molecular diagnostics portfolio, Meridian Bioscience remains focused on delivering reliable testing solutions that assist laboratories, healthcare providers, and families in improving patient care across a broad range of infectious diseases.
About Meridian Bioscience, Inc.
Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic and life science products. We are dedicated to developing and delivering better solutions that give answers with speed, accuracy, and simplicity that are redefining the possibilities of life from discovery to diagnosis. Through discovery and development, we provide critical life science raw materials used in immunological and molecular tests for human, animal, plant, and environmental applications.
Through diagnosis, we provide diagnostic solutions in areas including gastrointestinal and upper respiratory infections and blood lead level testing. We build relationships and provide solutions to hospitals, reference laboratories, research centers, veterinary testing centers, physician offices, diagnostics manufacturers, and biotech companies in more than 70 countries around the world.